...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>PLoS One >Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study
【24h】

Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study

机译：冠状动脉疾病的严重程度与非酒精性脂肪性肝病相关：单盲前瞻性单中心研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and aims Liver steatosis has shown to be associated with coronary artery disease (CAD). The aim of our study was to evaluate the association between the presence and severity of CAD and Non-alcoholic fatty liver disease (NAFLD) assessed by transient elastography (TE) and controlled attenuation parameter (CAP). Methods 576 Patients undergoing coronary angiography were enrolled in this prospective study, receiving at least 10 TE and CAP measurements using the FibroScan® M-probe. Clinically relevant CAD (CAD 3) was defined as stenosis with ≥75% reduction of the luminal diameter. NAFLD was determined by CAP ≥234 dB/m. NAFLD with advanced fibrosiswas determined by TE-values ≥7.9kPa in the presence of NAFLD and absence of congestive or right-sided heart failure. Rates and 95% confidence intervals are shown. Results 505 patients were available for analysis of NAFLD. However, only 392 patients were available for analysis of NAFLD with advanced fibrosis, since 24 patients had to be excluded due to non valid TE-measurements and 89 patients due to congestive or right-sided heart failure or suspected concomitant liver disease, respectively. 70.5% (66.3%-74.4%) of patients had CAD 3, 71.5% (67.3%-75.4%) were diagnosed with NAFLD, and 11.2% (8.3%-14.8%) with NAFLD with advanced fibrosis. Patients with CAD 3 had higher median CAP-values (273±61 vs. 260±66 dB/m; p = 0.038) and higher degrees of steatosis as compared to patients without CAD 3. While NAFLD was significantly more often diagnosed in patients with CAD 3 (75.0% vs. 63.1%, p = 0.0068), no significant difference was found for NAFLD with advanced fibrosis (10.7% vs. 12.5%, p = 0.60). Conclusions Clinically relevant CAD is frequently associated with the presence of NAFLD, but not NAFLD with advanced fibrosis.
机译：背景和目的肝脂肪变性已证明与冠状动脉疾病（CAD）相关。我们研究的目的是评估通过瞬时弹性成像（TE）和受控衰减参数（CAP）评估的CAD与非酒精性脂肪肝疾病（NAFLD）的存在和严重程度之间的关联。方法576名接受冠状动脉造影术的患者参加了这项前瞻性研究，使用FibroScan®M-probe进行了至少10次TE和CAP测量。临床相关的CAD（CAD 3）被定义为狭窄，且管腔直径缩小≥75％。 NAFLD由CAP≥234dB / m确定。在存在NAFLD且不存在充血性或右侧心力衰竭时，TE≥7.9kPa确定患有晚期纤维化的NAFLD。显示了比率和95％置信区间。结果505例患者可用于NAFLD分析。但是，只有392例患者可用于分析晚期纤维化的NAFLD，因为分别由于无效的TE测量必须排除24例患者，以及由于充血性或右侧心力衰竭或疑似伴随肝病而导致的89例患者。 70.5％（66.3％-74.4％）的患者患有CAD 3，被诊断为NAFLD的患者为71.5％（67.3％-75.4％），患有晚期纤维化的NAFLD的患者为11.2％（8.3％-14.8％）。与没有CAD 3的患者相比，CAD 3的患者具有更高的中位CAP值（273±61 vs. 260±66 dB / m; p = 0.038）和更高的脂肪变性。 CAD 3（75.0％比63.1％，p = 0.0068），发现晚期纤维化NAFLD差异无统计学意义（10.7％vs. 12.5％，p = 0.60）。结论临床上相关的CAD通常与NAFLD的存在有关，但与晚期纤维化的NAFLD无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号